Evolve BioSystems is dedicated to developing the next generation of products to establish, restore, and maintain a healthy newborn gut microbiome.
Building on a decade of expertise in the partnership between the infant gut microbiome and human breast milk, Evolve is solving newborn gut dysbiosis, or an imbalance beneficial bacteria, through microbiome-based interventions in both human and animal health.
Evolve BioSystems, makers of Evivo® baby probiotic, today announced that its flagship consumer product Evivo is now available in Hong Kong and Singapore.
A new study published in mSphere found that children with higher levels of the beneficial bacteria, Bifidobacterium, in their gut microbiome had reduced abundance and lower frequency of antimicrobial resistance (AMR) genes.
Evivo® infant stool test prototype is the first ever point-of-care screening test to provide a clear window into infant gut health
The beneficial bacterium found in Evivo® baby probiotic is clinically shown to support a protective intestinal environment in infants.
Evolve BioSystems, Inc. (www.evolvebiosystems.com) announced publication of a study showing that two weeks of supplementation with Bifidobacterium longum subsp. infantis EVC001 (B. infantis EVC001, currently available to consumers as Evivo® baby probiotic) in breastfed infants led to an 85 percent reduction in virulence factor genes, the tools which enable pathogens to thrive and cause infection in humans.
Bill & Melinda Gates Foundation, Li Ka Shing Foundation Lead New Funding Round to Expand Groundbreaking Progress in Restoring Infant Gut Microbiome and to Lay a Global Foundation for Long-Term Nutritional and Immune Health
Evolve BioSystems is please to announce that Dr. Bethany Henrick, Director of Immunology and Diagnostics, will be speaking at the upcoming American Society for Nutrition conference, Nutrition 2018, taking place in Boston, June 9-12.
Evolve Bio’s Dr. Casaburi will be speaking on Thursday, May 10th, in a presentation titled "Targeted probiotic supplementation reduces antibiotic resistance gene carriage in breastfed infants" where he will be sharing Evolve's latest research on the impact of activated B. infantis ECV001 on the risk of antibiotic resistance in infants.
Funded By the Bill & Melinda Gates Foundation, Study Between Evolve BioSystems and the International Centre for Diarrhoeal Disease Research Will Determine Impact of Evivo Probiotic on Infants with Severe Acute Malnutrition
Evolve BioSystems is please to announce that Dr. David Kyle, Evolve Board Chairman and CSO, will be speaking at the upcoming Translational Microbiome Conference, April 18-20 in Boston.